Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

2024-11-04

BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Event: Guggenheim Healthcare Innovation Conference
Date: November 13, 2024
Location: Boston, MA
Fireside Chat: 9:00 AM ET

Event: Jefferies London Healthcare Conference
Date: November 19, 2024
Location: London, UK
Fireside Chat: 1:30 PM GMT

Event: 7^th Annual Evercore HealthCONx Conference
Date: December 5, 2024
Location: Miami, FL
Fireside Chat: 10:00 AM ET

Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.

About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.

Contact:

Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2480078703"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2480078703\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2480078703?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WV6yE7zzagvQWe1Qs9uGAQ--~B/aD03NDt3PTMyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/397386a71f88bb21774f98da674ac72c","is_english":true,"pubTime":"2024-11-04 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480078703","market":"us","top_or_hot":-1,"title":"Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/WiumAX4Y3LFkta3sTzq87Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/84c11fd4c6d0c31ebbabcf154617bd18\" title=\"logo.png\" vspace=\"5\"/>\n<p>BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a> (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:</p>\n<p><strong>Event:</strong> Guggenheim Healthcare Innovation Conference <br/><strong>Date:</strong> November 13, 2024<br/><strong>Location:</strong> Boston, MA<br/><strong>Fireside Chat:</strong> 9:00 AM ET<br/><br/><br/></p>\n<p><strong>Event:</strong> Jefferies London Healthcare Conference <br/><strong>Date:</strong> November 19, 2024<br/><strong>Location: </strong>London, UK<br/><strong>Fireside Chat</strong>: 1:30 PM GMT<br/><br/><br/></p>\n<p><strong>Event:</strong> 7<sup>th</sup> Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference<br/><strong>Date:</strong> December 5, 2024<br/><strong>Location:</strong> Miami, FL<br/><strong>Fireside Chat:</strong> 10:00 AM ET<br/><br/><br/></p>\n<p>Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.</p>\n<p><strong>About Centessa Pharmaceuticals </strong><br/>Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.<br/></p>\n<p><strong>Contact: </strong></p>\n<p>Kristen K. Sheppard, Esq.<br/>SVP of Investor Relations<br/><u>investors@centessa.com</u><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2024-11-04 20:30</span>\n</p>\n</header>\n<article>\n<img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/WiumAX4Y3LFkta3sTzq87Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/84c11fd4c6d0c31ebbabcf154617bd18\" title=\"logo.png\" vspace=\"5\"/>\n<p>BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a> (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:</p>\n<p><strong>Event:</strong> Guggenheim Healthcare Innovation Conference <br/><strong>Date:</strong> November 13, 2024<br/><strong>Location:</strong> Boston, MA<br/><strong>Fireside Chat:</strong> 9:00 AM ET<br/><br/><br/></p>\n<p><strong>Event:</strong> Jefferies London Healthcare Conference <br/><strong>Date:</strong> November 19, 2024<br/><strong>Location: </strong>London, UK<br/><strong>Fireside Chat</strong>: 1:30 PM GMT<br/><br/><br/></p>\n<p><strong>Event:</strong> 7<sup>th</sup> Annual <a href=\"https://laohu8.com/S/EVR\">Evercore</a> HealthCONx Conference<br/><strong>Date:</strong> December 5, 2024<br/><strong>Location:</strong> Miami, FL<br/><strong>Fireside Chat:</strong> 10:00 AM ET<br/><br/><br/></p>\n<p>Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.</p>\n<p><strong>About Centessa Pharmaceuticals </strong><br/>Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.<br/></p>\n<p><strong>Contact: </strong></p>\n<p>Kristen K. Sheppard, Esq.<br/>SVP of Investor Relations<br/><u>investors@centessa.com</u><br/><br/></p>\n<br/>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/centessa-pharmaceuticals-participate-upcoming-investor-123000861.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTA","symbol_name":"Centessa Pharmaceuticals plc","start_time":0,"source_url":"https://finance.yahoo.com/news/centessa-pharmaceuticals-participate-upcoming-investor-123000861.html","article_id":"2480078703","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WV6yE7zzagvQWe1Qs9uGAQ--~B/aD03NDt3PTMyNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/397386a71f88bb21774f98da674ac72c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480078703","pubTimestamp":1730723400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"BOSTON and LONDON, Nov. 04, 2024  -- Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:. Event: Guggenheim Healthcare Innovation Conference Date: November 13, 2024Location: Boston, MAFireside Chat: 9:00 AM ET. Event: Jefferies London Healthcare Conference Date: November 19, 2024Location: London, UKFireside Chat: 1:30 PM GMT. Event: 7th Annual Evercore HealthCONx ConferenceDate: December 5, 2024Location: Miami, FLFireside Chat: 10:00 AM ET. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncol","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTA":"Centessa Pharmaceuticals plc","BK4139":"生物科技","BK4539":"次新股","BK4535":"淡马锡持仓"},"translate_title":"Centessa Pharmaceuticals将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9},"content_text":"BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:\nEvent: Guggenheim Healthcare Innovation Conference Date: November 13, 2024Location: Boston, MAFireside Chat: 9:00 AM ET\nEvent: Jefferies London Healthcare Conference Date: November 19, 2024Location: London, UKFireside Chat: 1:30 PM GMT\nEvent: 7th Annual Evercore HealthCONx ConferenceDate: December 5, 2024Location: Miami, FLFireside Chat: 10:00 AM ET\nAccess to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.\nAbout Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.\nContact: \nKristen K. Sheppard, Esq.SVP of Investor Relationsinvestors@centessa.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}